Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in:

Open Access 01-12-2024 | Analysis

Evaluating KLHDC8A as a biomarker for glioma: impact on survival and proliferation through the Wnt/β-catenin pathway

Authors: Yu Tian, Xiaofei Hu, Xiaoling Wang, Youcai Huang, Junfeng Hao, Yu Guo, Chao Zhu, Yanyang Tu

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Glioma is one of the most common malignant tumors and shows a high metastasis rate and poor prognosis. KLHDC8A has been implicated in several cancers, but its role in glioma and its potential as a biomarker remain unclear. We conducted a pan-cancer analysis of KLHDC8A using multiple databases and assessed its expression levels, survival associations, and diagnostic utility. Kaplan–Meier survival analysis and Receiver Operating Characteristic (ROC) curves were utilized to evaluate KLHDC8A’s prognostic and diagnostic potential. Additionally, we investigated KLHDC8A's role in glioma cell proliferation and its involvement in the Wnt/β-catenin signaling pathway. Our pan-cancer analysis revealed significant dysregulation of KLHDC8A across various tumors. Elevated KLHDC8A expression was associated with poor overall survival (OS) in cancers including ACC, KIRP, LGG, and STAD. Disease-specific survival (DSS) analysis indicated worse outcomes in ACC, KIRP, and LGG with high KLHDC8A levels. ROC curve analysis demonstrated KLHDC8A's strong diagnostic potential for glioblastoma multiforme (GBM) and lower-grade gliomas (LGG), with AUC values of 0.920 and 0.748, respectively. In glioma patients, high KLHDC8A expression correlated with shorter OS and DSS in LGG, while no significant correlation was observed in GBM. Multivariate Cox regression confirmed KLHDC8A as an independent prognostic factor for OS and DSS in LGG. Knockdown experiments in glioma cell lines U251 and U87 showed that KLHDC8A silencing led to reduced cell proliferation and colony formation, which was associated with downregulation of key proteins in the Wnt/β-catenin pathway. Overall, KLHDC8A is a promising biomarker for the diagnosis and prognosis of LGG, and its high expression is linked to poor survival outcomes. The gene's involvement in the Wnt/β-catenin signaling pathway underscores its role in glioma progression, highlighting KLHDC8A’s potential as a therapeutic target and diagnostic marker, particularly for LGG.
Literature
1.
Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–52.PubMedCrossRef
2.
Schaff LR, Mellinghoff IK. A review of glioblastoma and other primary brain malignancies-reply. JAMA. 2023;330:189–90.PubMedCrossRef
3.
Kim JH, Huse JT, Huang Y, Lyden D, Greenfield JP. Molecular diagnostics in paediatric glial tumours. Lancet Oncol. 2013;14:e19-27.PubMedCrossRef
4.
5.
Malta TM, de Souza CF, Sabedot TS, Silva TC, Mosella MS, Kalkanis SN, Snyder J, Castro AVB, Noushmehr H. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 2018;20:608–20.PubMedCrossRef
6.
Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–8.PubMedCrossRef
7.
Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273–80.PubMedCrossRef
8.
Hotchkiss KM, Batich KA, Mohan A, Rahman R, Piantadosi S, Khasraw M. Dendritic cell vaccine trials in gliomas: untangling the lines. Neuro Oncol. 2023;25:1752–62.PubMedPubMedCentralCrossRef
9.
10.
11.
12.
Choi J, Bordeaux ZA, McKeel J, Nanni C, Sutaria N, Braun G, Davis C, Miller MN, Alphonse MP, Kwatra SG, West CE, Kwatra MM. GZ17–6.02 inhibits the growth of EGFRvIII+ glioblastoma. Int J Mol Sci. 2022;23:4174.PubMedPubMedCentralCrossRef
13.
14.
Zhu X, Chen T, Yang H, Lv K. Lactate induced up-regulation of KLHDC8A (Kelch domain-containing 8A) contributes to the proliferation, migration and apoptosis of human glioma cells. J Cell Mol Med. 2020;24:11691–702.PubMedPubMedCentralCrossRef
15.
Liu B, Su Q, Xiao B, Zheng G, Zhang L, Yin J, Wang L, Che F, Heng X. RAB42 promotes glioma pathogenesis via the VEGF signaling pathway. Front Oncol. 2021;11: 657029.PubMedPubMedCentralCrossRef
16.
Yu Z, Li J, Jiang J, Li Y, Lin L, et al. miRNA-128-3p inhibits malignant behavior of glioma cells by downregulating KLHDC8A expression. Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1447–59.PubMed
17.
Zhang L, Wu X, Fan X, Ai H. MUM1L1 as a tumor suppressor and potential biomarker in ovarian cancer: evidence from bioinformatics analysis and basic experiments. Comb Chem High Throughput Screen. 2023;26:2487–501.PubMedCrossRef
18.
Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10:468–77.PubMedCrossRef
19.
Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.PubMedCrossRef
20.
21.
Nicholson JG, Fine HA. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov. 2021;11:575–90.PubMedCrossRef
22.
Wang J, Yang ZY, Guo YF, Kuang JY, Bian XW, Yu SC. Targeting different domains of gap junction protein to control malignant glioma. Neuro Oncol. 2018;20:885–96.PubMedCrossRef
23.
Poff A, Koutnik AP, Egan KM, Sahebjam S, D’Agostino D, Kumar NB. Targeting the warburg effect for cancer treatment: ketogenic diets for management of glioma. Semin Cancer Biol. 2019;56:135–48.PubMedCrossRef
24.
Regmi M, Wang Y, Liu W, Dai Y, Liu S, Ma K, Lin G, Yang J, Liu H, Wu J, Yang C. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. J Exp Clin Cancer Res. 2024;43:47.PubMedPubMedCentralCrossRef
25.
Ma Y, Yi J, Ruan J, Ma J, Yang Q, Zhang K, Zhang M, Zeng G, Jin L, Huang X, Li J, Yang H, Wu W, Sun D. Engineered cell membrane-coated nanoparticles: new strategies in glioma targeted therapy and immune modulation. Adv Healthc Mater. 2024;13: e2400514.PubMedCrossRef
26.
Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma. Nat Rev Dis Primers. 2024;10:33.PubMedCrossRef
27.
Salvalaggio A, Pini L, Bertoldo A, Corbetta M. Glioblastoma and brain connectivity: the need for a paradigm shift. Lancet Neurol. 2024;23:740–8.PubMedCrossRef
28.
Wu J, Heidelberg RE, Gajjar A. Adolescents and young adults with cancer: CNS tumors. J Clin Oncol. 2024;42:686–95.PubMedCrossRef
29.
Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17:31.PubMedPubMedCentralCrossRef
30.
Jayaram MA, Phillips JJ. Role of the microenvironment in glioma pathogenesis. Annu Rev Pathol. 2024;19:181–201.PubMedCrossRef
31.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:932–44.PubMedCrossRef
32.
Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21:39.PubMedPubMedCentralCrossRef
33.
Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger AB. New approaches to glioblastoma. Annu Rev Med. 2022;73:279–92.PubMedCrossRef
34.
Pienkowski T, Kowalczyk T, Garcia-Romero N, Ayuso-Sacido A, Ciborowski M. Proteomics and metabolomics approach in adult and pediatric glioma diagnostics. Biochim Biophys Acta Rev Cancer. 2022;1877: 188721.PubMedCrossRef
35.
Papavassiliou KA, Papavassiliou AG. Transcription factors in glioblastoma—molecular pathogenesis and clinical implications. Biochim Biophys Acta Rev Cancer. 2022;1877: 188667.PubMedCrossRef
36.
Hayat R, Manzoor M, Hussain A. Wnt signaling pathway: a comprehensive review. Cell Biol Int. 2022;46:863–77.PubMedCrossRef
37.
Huang P, Yan R, Zhang X, Wang L, Ke X, Qu Y. Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities. Pharmacol Ther. 2019;196:79–90.PubMedCrossRef
38.
39.
Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131–8.PubMedCrossRef
40.
Isa AI. Exploring signaling pathway crosstalk in glioma by mapping miRNA and WNT pathways: a review. Int J Biol Macromol. 2024;257: 128722.PubMedCrossRef
41.
Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung WK, Medema RH, He X, Huang S. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 2011;20:427–42.PubMedPubMedCentralCrossRef
42.
Yue X, Cao D, Lan F, Pan Q, Xia T, Yu H. MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7. Neuro Oncol. 2016;18:1288–96.PubMedPubMedCentralCrossRef
43.
Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, Kogner P, Baryawno N, Johnsen JI. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun. 2015;6:8904.PubMedCrossRef
44.
Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E, Fruttiger M, Taketo MM, Dimmeler S, Plate KH, Liebner S. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med. 2012;209:1611–27.PubMedPubMedCentralCrossRef
45.
46.
Chen Y, Fang R, Yue C, Chang G, Li P, Guo Q, Wang J, Zhou A, Zhang S, Fuller GN, Shi X, Huang S. Wnt-induced stabilization of KDM4C is required for Wnt/β-catenin target gene expression and glioblastoma tumorigenesis. Cancer Res. 2020;80:1049–63.PubMedCrossRef
Metadata
Title
Evaluating KLHDC8A as a biomarker for glioma: impact on survival and proliferation through the Wnt/β-catenin pathway
Authors
Yu Tian
Xiaofei Hu
Xiaoling Wang
Youcai Huang
Junfeng Hao
Yu Guo
Chao Zhu
Yanyang Tu
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-01625-6

Other articles of this Issue 1/2024

RBMS1 interference inhibits malignant progression of glioblastoma cells and promotes ferroptosis

Stratification and prognostic evaluation of breast cancer subtypes defined by obesity-associated genes

Bibliometric analysis of endoplasmic reticulum stress in hepatocellular carcinoma: trends and future directions

A real-world study of active vitamin D as a prognostic marker in patients with sarcoma

Establishment and validation of a novel disulfidptosis-related immune checkpoint gene signature in clear cell renal cell carcinoma

Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma

  • Open Access
  • Correction

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits